MAIA Biotechnology, Inc.
MAIA
$-0.07
Change (1 day)
$5.99
Year High
$0.82
Year Low
Categories
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.
Earnings for MAIA Biotechnology, Inc. (MAIA)
Earnings in 2023 (TTM): $-19,772,905
According to MAIA Biotechnology, Inc.'s latest financial reports the company's current earnings (TTM) are $-19,772,905. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MAIA Biotechnology, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-19,772,905 | $-19,772,905 |
| 2022 | $-15,769,279 | $-15,805,968 |
| 2021 | $-12,578,211 | $-13,285,741 |
| 2020 | $-6,959,248 | $-6,668,207 |
| 2019 | $-6,921,114 | $-6,492,782 |